LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04), Zacks reports.
LENZ Therapeutics Stock Performance
NASDAQ LENZ traded up $0.19 during trading on Friday, reaching $26.49. 502,876 shares of the company's stock were exchanged, compared to its average volume of 166,499. The stock has a market cap of $728.50 million, a P/E ratio of -5.55 and a beta of 0.58. The company has a 50 day moving average price of $24.15 and a two-hundred day moving average price of $27.06. LENZ Therapeutics has a 1 year low of $14.42 and a 1 year high of $38.93.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on LENZ. TD Cowen began coverage on LENZ Therapeutics in a report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 target price for the company. Citigroup lifted their target price on LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, LENZ Therapeutics currently has a consensus rating of "Buy" and an average target price of $41.67.
Read Our Latest Stock Report on LENZ Therapeutics
LENZ Therapeutics Company Profile
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
See Also
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
